http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109157522-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-485 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 |
| filingDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109157522-B |
| titleOfInvention | Pharmaceutical composition containing sitagliptin or pharmaceutically acceptable salt thereof, preparation method and application thereof |
| abstract | The invention relates to a pharmaceutical composition comprising sitagliptin, a pharmaceutically acceptable salt thereof and/or a hydrate of the salt, and anhydrous calcium hydrogen phosphate. The pharmaceutical composition is further used for preparing solid preparations, in particular tablets by a direct compression method. By selecting the pharmaceutical composition of the invention, particularly specific anhydrous calcium hydrogen phosphate as a raw material, the quality control mode of the pharmaceutical composition taking sitagliptin, pharmaceutically acceptable salt thereof and/or hydrate of the salt as an active ingredient can be remarkably improved, and even the generation of related impurities in the pharmaceutical composition can be remarkably improved, so that the stability of the pharmaceutical composition and related dosage forms can be improved. |
| priorityDate | 2018-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 104.